Brief: Aktis Oncology Receives U.S. FDA Fast Track Designation For Aky-1189
24/02/2026 13:18
Feb 24 (Reuters) - Aktis Oncology Inc AKTS.O: AKTIS ONCOLOGY RECEIVES U.S. FDA FAST TRACK DESIGNATION FOR AKY-1189, A NECTIN-4 MINIPROTEIN RADIOCONJUGATE Source text: ID:nGNX2mwgh0 Further company coverage: AKTS.O (((( Reuters.briefs@thomsonreuters.com ;));))
Recent news on Aktis Oncology
See all newsAktis Oncology Q2 net loss widens on higher R&D, administrative costs
U.S. RESEARCH ROUNDUP-Danaher, GM, MSCI
Aktis Oncology Q1 net loss widens on increased IPO-related expenses
Generate Biomedicines shares fall 6% in weak Nasdaq debut for drug developer (updated)
Flagship-backed Generate Biomedicines shares fall 6% in Nasdaq debut